CDEK
← All organizations
Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

For profitContributed to NMEWebsite ↗

Also known as: Agios Pharmaceuticals | Agios Pharmaceuticals, Inc. | AGIOS PHARMS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Aug 27, 2013

First marketed drug

Jul 20, 2018

First NDA

Jul 20, 2018

Last known activity

Mar 31, 2026

Acquired by Servier on Dec 21, 2020

Timeline

2000s

  1. Jul 1, 2007

    Agios Pharmaceuticals, Inc.— Founded

2010s

  1. Jul 20, 2018

    ivosidenib— NDA Organization

  2. Jul 20, 2018

    ivosidenib— NDA Secondary Org

2020s

  1. Dec 21, 2020

    Servier— Acquired By

  2. Feb 17, 2022

    mitapivat— Marketing Organization

Drugs by trial phase (29 distinct, 62 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 3 (3 own, 0 via acquisition)

Phase 2 (5 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Recent trials (50)

Details

Founded
Cambridge, MA, US Jul 1, 2007
First NDA
Jul 20, 2018
Last known activity
Mar 31, 2026

Designations held

  • Orphan drug
  • Fast track
  • Priority review